Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Osteopontin Levels in Patients with Papillary Thyroid Cancer According to the Presence of Hashimoto's Thyroiditis

  • Park, So-Hyun (Department of Endocrinology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Chan-Sung (Department of Endocrinology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kim, Young-Il (Department of Endocrinology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Nam-Goong, Il-Seong (Department of Endocrinology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kim, Yon-Seon (Department of General Surgery, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Lee, Jong-Cheol (Department of Otolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Choi, Jung-Il (Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Jeong-Woo (Department of Biological Sciences, University of Ulsan) ;
  • Kim, Eun-Sook (Department of Endocrinology, Ulsan University Hospital, University of Ulsan College of Medicine)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Human papillary thyroid carcinoma (PTC) is often associated with Hashimoto's thyroiditis (HT); their coexistence improves PTC prognosis. Osteopontin, a secreted glycoprotein, plays a role in cell survival, immunity, and tumor progression, its expression being associated with a poor prognosis and metastasis in several malignancies. Osteopontin overexpression correlates with aggressive clinicopathological features in PTC. Lymph node metastases and large tumor size positively correlate with osteopontin positivity. This study aimed to: (1) confirm osteopontin overexpression in human PTC samples; (2) compare osteopontin expression levels in PTC cases with and without HT; and (3) identify correlations between tumor aggressiveness and osteopontin expression levels. Materials and Methods: Plasma osteopontin was assessed in 45 patients with PTC, 22 patients with PTC and HT, and 24 healthy controls by enzyme-linked immunosorbent assay. Thyroid tissue osteopontin mRNA and protein levels were analyzed by reverse transcription-polymerase chain reaction and Western blotting, respectively. Results: Plasma osteopontin levels were significantly higher in PTC patients than in healthy controls. Plasma osteopontin, tissue osteopontin mRNA, and tissue osteopontin protein levels were significantly lower in patients with PTC and HT than in those with PTC alone. In advanced disease stage cases, osteopontin mRNA and protein expression levels were lower in patients with PTC and HT than in those with PTC alone. However, the osteopontin expression level was not significantly associated with the TNM stage. Conclusions: Plasma osteopontin, tissue osteopontin mRNA, and tissue osteopontin protein levels were significantly lower in patients with PTC and HT than in those with PTC alone, suggesting that HT attenuates PTC aggressiveness through negative regulation of osteopontin expression.

Keywords

References

  1. Ahn D, Heo SJ, Park JH, et al (2011). Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol, 50, 1228-34. https://doi.org/10.3109/0284186X.2011.602109
  2. Briese J, Cheng S, Ezzat S, et al (2010). Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res, 30, 1681-8.
  3. Dailey, M.E., Lindsay, S. Skahen, R (1955). Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. A.M.A. Arch Surg, 70, 291-7. https://doi.org/10.1001/archsurg.1955.01270080137023
  4. Fedarko NS, Jain A, Karadag A, et al (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 7, 4060-6.
  5. Fiore E, Rago T, Latrofa F, et al (2011). Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer, 18, 429-37. https://doi.org/10.1530/ERC-11-0028
  6. Giachelli CM, Steitz S (2000). Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol, 19, 615-22. https://doi.org/10.1016/S0945-053X(00)00108-6
  7. Guarino V, Faviana P, Salvatore G, et al (2005). Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab, 90, 5270-8. https://doi.org/10.1210/jc.2005-0271
  8. Hollowell JG, Staehling NW, Flanders WD et al (2002). SerumTSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metabolism, 87, 489-99. https://doi.org/10.1210/jcem.87.2.8182
  9. Huang BY, Hseuh C, Chao TC, et al (2011). Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol, 22, 144-9. https://doi.org/10.1007/s12022-011-9164-9
  10. Hundahl SA, Fleming ID, Fremgen AM et al (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-48. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
  11. Kashima K, Yokoyama S, Noguchi S, et al (1998). Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid, 8, 197-202. https://doi.org/10.1089/thy.1998.8.197
  12. Kim EY, Kim WG, Kim WB, et al (2009). Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf), 71, 581-6. https://doi.org/10.1111/j.1365-2265.2009.03537.x
  13. Kim KW, Park YJ, Kim EH, et al (2011). Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck, 33, 691-5. https://doi.org/10.1002/hed.21518
  14. Kim SS, Lee BJ, Lee JC, et al (2011). Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck, 33, 1272-7. https://doi.org/10.1002/hed.21594
  15. Kwak JY, Kim EK, Kim JK, et al (2010). Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation prevalent area. Head Neck, 32, 490-8.
  16. Kyung Ho Kang (2013). Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc, 84, 9-17. https://doi.org/10.4174/jkss.2013.84.1.9
  17. Liu W, Li Z, Luo Q, et al (2011). The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity. Am J Rhinol Allergy, 25, 313-7. https://doi.org/10.2500/ajra.2011.25.3662
  18. Loh KC, Greenspan FS, Dong F, et al (1999). Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 84, 458-63. https://doi.org/10.1210/jcem.84.2.5443
  19. Oates AJ, Barraclough R, Rudland PS (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13, 97-104.
  20. Rittling SR, Chambers AF (2004). Role of osteopontin in tumour progression. Br J Cancer, 90, 1877-81. https://doi.org/10.1038/sj.bjc.6601839
  21. Singh B, Shaha AR, Trivedi H, et al (1999). Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery, 126, 1070-6. https://doi.org/10.1067/msy.2099.101431
  22. Wang KX, Denhardt DT (2008). Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev, 19, 333-45. https://doi.org/10.1016/j.cytogfr.2008.08.001